Please assess the completion status of the following clinical trial:

Trial Title: Dexmedetomidine as Adjunctive Therapy for Alcohol Withdrawal

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Severe alcohol withdrawal defined by a CIWA score ≥ 15 and the need for at least 16 mg of lorazepam over a four-hour period. All lorazepam doses, whether oral or intravenous, will contribute to the cumulative amount.~2. Patients receiving standard therapy for severe alcohol withdrawal according to a symptom-triggered alcohol withdrawal protocol. Lorazepam is the preferred benzodiazepine agent for patients requiring ICU admission due to alcohol withdrawal.~3. Informed consent within 36 hours of qualifying for the study.~Exclusion Criteria:~1. Patients \< 18 years of age or \> 85 years of age.~2. Patients receiving benzodiazepine therapy for purposes other than alcohol withdrawal (e.g. sedation).~3. Patients with alcohol withdrawal not requiring ICU admission.~4. Patients receiving epidural administration of medication(s).~5. Comatose patients by metabolic or neurologic affectation.~6. Patients with active myocardial ischemia or second- or third-degree heart block.~7. Moribund state with planned withdrawal of life support.~8. Patients with known or suspected severe adverse reactions to dexmedetomidine (or clonidine).~9. Pregnant females or females suspected of being pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Dexmedetomidine, low dose (Type: EXPERIMENTAL): Dexmedetomidine 0.4 µg/kg per hour administered for a maximum duration of five days
- Dexmedetomidine, high dose (Type: EXPERIMENTAL): Dexmedetomidine 1.2 µg/kg per hour administered for a maximum duration of five days
- Placebo (Type: PLACEBO_COMPARATOR): Normal saline

Based on this trial design, predict the completion outcome and termination type (if applicable).